Literature DB >> 8599490

Coacaethylene levels in patients who test positive for cocaine.

D Brookoff1, M F Rotondo, L M Shaw, E A Campbell, L Fields.   

Abstract

STUDY
OBJECTIVE: To determine the presence of cocaethylene, an active metabolite of the combination of cocaine and ethanol, among trauma patients who test positive for cocaine.
METHODS: We assembled a case series of 416 consecutive urban trauma center patients with major trauma. Urine was tested for the presence of the cocaine metabolite benzoylecgonine. Plasma was quantitatively assayed for cocaine, ethanol, and cocaethylene.
RESULTS: Of the study subjects, 158 (38%) were positive for benzoylecgonine. Of the 114 of these subjects who had adequate plasma specimens, 68 (60%) tested positive for cocaethylene (mean, 41 +/- 27 ng/mL; range, 3 to 213 ng/mL), all tested positive for cocaine (mean, 92.9 +/- 52 ng/mL), and 56% were positive for ethanol (mean, 175 +/- 85 mg/mL). We found poor correlation between admission levels of cocaethylene and cocaine (R=.02), even when subjects were stratified by ethanol level. The correlation between cocaethylene and ethanol levels was weak (R=.24). Of the 68 patients who tested positive for cocaethylene, 29% tested negative for ethanol. Plasma was also assayed from 94 subjects who tested negative for benzoylecgonine; 9% had detectable levels of cocaine, and 2% had detectable levels of cocaethylene.
CONCLUSION: Cocaethylene was present in more than half of the subjects who tested positive for cocaine.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8599490     DOI: 10.1016/s0196-0644(96)70266-4

Source DB:  PubMed          Journal:  Ann Emerg Med        ISSN: 0196-0644            Impact factor:   5.721


  8 in total

1.  Elevated cortisol and learning and memory deficits in cocaine dependent individuals: relationship to relapse outcomes.

Authors:  Helen C Fox; Eric D Jackson; Rajita Sinha
Journal:  Psychoneuroendocrinology       Date:  2009-04-16       Impact factor: 4.905

2.  Alcohol-preferring (P) rats are more sensitive than Wistar rats to the reinforcing effects of cocaine self-administered directly into the nucleus accumbens shell.

Authors:  Simon N Katner; Scott M Oster; Zheng-Ming Ding; Gerald A Deehan; Jamie E Toalston; Sheketha R Hauser; William J McBride; Zachary A Rodd
Journal:  Pharmacol Biochem Behav       Date:  2011-06-25       Impact factor: 3.533

3.  Cocaine influences alcohol-seeking behavior and relapse drinking in alcohol-preferring (P) rats.

Authors:  Sheketha R Hauser; Jessica A Wilden; Gerald A Deehan; William J McBride; Zachary A Rodd
Journal:  Alcohol Clin Exp Res       Date:  2014-10       Impact factor: 3.455

4.  Increased serum brain-derived neurotrophic factor is predictive of cocaine relapse outcomes: a prospective study.

Authors:  Carrol D'Sa; Helen C Fox; Adam K Hong; Ralph J Dileone; Rajita Sinha
Journal:  Biol Psychiatry       Date:  2011-07-08       Impact factor: 13.382

5.  Ethanol consumption reduces the adverse consequences of self-administered intravenous cocaine in rats.

Authors:  L A Knackstedt; A Ettenberg
Journal:  Psychopharmacology (Berl)       Date:  2004-08-25       Impact factor: 4.530

Review 6.  The orexin (hypocretin) neuropeptide system is a target for novel therapeutics to treat cocaine use disorder with alcohol coabuse.

Authors:  Morgan H James; Jennifer E Fragale; Shayna L O'Connor; Benjamin A Zimmer; Gary Aston-Jones
Journal:  Neuropharmacology       Date:  2020-10-19       Impact factor: 5.250

7.  Pharmacodynamic evaluation of the cardiovascular effects after the coadministration of cocaine and ethanol.

Authors:  S Casey Laizure; Robert B Parker
Journal:  Drug Metab Dispos       Date:  2008-11-12       Impact factor: 3.922

8.  Sequential cocaine-alcohol self-administration produces adaptations in rat nucleus accumbens core glutamate homeostasis that are distinct from those produced by cocaine self-administration alone.

Authors:  Bethany A Stennett; Yasmin Padovan-Hernandez; Lori A Knackstedt
Journal:  Neuropsychopharmacology       Date:  2019-07-02       Impact factor: 8.294

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.